US SEC Trading Suspension Halt Orders — September 01, 2026
This digest covers 8 regulatory filings from September 1, 2026, all centered on Nasdaq trading suspensions, delistings, and regulatory halts. A dominant theme is the wave of late Form 10-Q filings: XTI Aerospace, Borealis Foods, CID Holdco, and Heritage Distilling all received deficiency notices for failing to file their Q2 2026 reports, with compliance plans due by late October 2026. The most severe event is BioXcel Therapeutics' Chapter 11 bankruptcy filing, which carries a 10/10 materiality rating and creates near-certain zero recovery for common stockholders. Barinthus Biotherapeutics is proceeding with a court-sanctioned merger that will halt trading on September 9, 2026, representing a clean delisting event. authID faces a dual compliance crisis—both a bid price deficiency and a stockholders' equity shortfall—significantly raising its delisting risk. U.S. GoldMining's audit committee independence issue is the least critical, with a cure period extending into 2027. Period-over-period data is limited across these filings as most are event-driven 8-Ks, but the concentration of late filings (4 of 8) suggests a systemic reporting bottleneck among micro-cap issuers. No insider trading activity or capital allocation changes were reported in any filing, reinforcing the distressed nature of these companies.